Marella Thorell Resigns as EVP and CFO of Seres Therapeutics
PUBLIC · MCRBOct 26, 2026
Position
Chief Financial Officer
Company
Seres Therapeutics
Marella Thorell
CambridgeBiotechnologyHealth CareTherapeutics
Description
On October 22, 2026, Marella Thorell announced her resignation from her role as Executive Vice President and Chief Financial Officer of Seres Therapeutics, effective November 15, 2026. After her departure, she will provide advisory services to support a smooth transition. The terms of her advisory services are yet to be finalized.
Who to call at Seres Therapeutics, and when
A new leader at Seres Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.
An alert the day Seres Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Seres Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Seres Therapeutics. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Seres Therapeutics
Location
Cambridge, Massachusetts, United States
About
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Seres’ lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiome therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Seres Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
CambridgeBiotechnologyHealth CareTherapeutics